← back to search

Matthew Chau Hsien Ng

Agency for Science, Technology and Research · SG
Area of research
Molecular Biology · Pulmonary and Respiratory Medicine
Research interest
Research interests include RNA modifications and cancer, Fibroblast Growth Factor Research, RNA regulation and disease, and Gastric Cancer Management and Outcomes.
h-index
19
citations
1,496
works
132
NIH funding
primary concept
Medicine
email

Recent publications

A deep-learning model for quantifying circulating tumour DNA from the density distribution of DNA-fragment lengths
Nature Biomedical Engineering 2025cited by 14position: middledoi
Spatial profiling of patient-matched HER2 positive gastric cancer reveals resistance mechanisms to targeted therapy
Gut 2025cited by 9position: middledoi
Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with gastric cancer
ESMO Open 2024cited by 87position: middledoi
Spatially Resolved Niche and Tumor Microenvironmental Alterations in Gastric Cancer Peritoneal Metastases
Gastroenterology 2024cited by 46position: middledoi
Phase I PIANO trial—PIPAC-oxaliplatin and systemic nivolumab combination for gastric cancer peritoneal metastases: clinical and translational outcomes
ESMO Open 2024cited by 15position: middledoi
Margetuximab plus pembrolizumab in patients with previously treated, HER2-positive gastro-oesophageal adenocarcinoma (CP-MGAH22–05): a single-arm, phase 1b–2 trial
The Lancet Oncology 2020cited by 189position: middledoi
Molecular Characterization and Clinical Outcomes in RET-Rearranged NSCLC
Journal of Thoracic Oncology 2020cited by 54position: middledoi
Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with metastatic gastric cancer: a JSMO–ESMO initiative endorsed by CSCO, KSMO, MOS, SSO and TOS
Annals of Oncology 2018cited by 220position: middledoi
Phase 1b/2 study of margetuximab (M) plus pembrolizumab (P) in advanced HER2+ gastroesophageal junction (GEJ) or gastric (G) adenocarcinoma (GEA).
Journal of Clinical Oncology 2018cited by 16position: middledoi
Phase Ib study of BGJ398 in combination with BYL719 in patients (pts) with select advanced solid tumors.
Journal of Clinical Oncology 2016cited by 17position: middledoi

Grants

No grants ingested yet.

Frequent collaborators

A. Craig Lockhart · Medical University of South Carolina2 papers (2016–2018)Philippe A. Cassier · University College London1 papers (2016–2016)Johanna C. Bendell · Roche (Switzerland)1 papers (2018–2018) · 1 papers (2018–2018)Gillianne Lai · National University of Singapore1 papers (2020–2020) · 1 papers (2018–2018)Philip J. Gold · Seattle University1 papers (2018–2018)Wan‐Teck Lim · National Cancer Centre Singapore1 papers (2020–2020)Ravindran Kanesvaran · SingHealth1 papers (2020–2020)Tira J. Tan · Khoo Teck Puat Hospital1 papers (2020–2020)Phillipe Bedard · Princess Margaret Cancer Centre1 papers (2016–2016)Quan Sing Ng · National Cancer Centre Singapore1 papers (2020–2020) · 1 papers (2016–2016)Florian Lordick · Leipzig University1 papers (2018–2018)Jon M. Wigginton · Smilow Cancer Hospital1 papers (2018–2018)Se Hoon Park · Korea Brain Research Institute1 papers (2018–2018)John Sarantopoulos · Cancer Clinic1 papers (2016–2016) · 1 papers (2018–2018)Elena Garralda · University College London1 papers (2016–2016)Ronan J. Kelly · Baylor University Medical Center1 papers (2018–2018)